Skip to main content

Advertisement

SpringerLink
Log in

Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Chemotherapy-treated patients with advanced Hodgkin’s disease (HD) differ considerably in acute hematotoxicity. Hematotoxicity may be indicative of pharmacological and metabolic heterogeneity. We hypothesized that low hematotoxicity might correlate with reduced systemic dose and thus reduced disease control. A total of 266 patients with advanced HD treated with cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD) were analyzed (HD6 trial of the German Hodgkin’s Lymphoma Study Group). The reported WHO grade of leukocytopenia was averaged over chemotherapy cycles given and weighted with the reciprocal dose intensity of the corresponding cycle. The low and high toxicity groups were defined in retrospect as having had an averaged WHO grade of leukocytopenia ≤2.1 and >2.1, respectively. The independent impact of low hematological toxicity on freedom from treatment failure (FFTF) was assessed multivariately adjusting for the international prognostic score for advanced HD. The results were validated in two independent cohorts [181 patients treated with COPP-ABVD (HD9-trial) and 250 patients treated with COPP-ABV-ifosfamide, methotrexate, etoposide, and prednisone (IMEP) (HD6 trial)]. The 5-year FFTF rates were 68% for patients with high toxicity vs 47% for patients with low toxicity [multivariate relative risk (RR) 2.0, 95% confidence interval (CI) 1.4–3.0, p=0.0002]. Patients with low toxicity received significantly higher nominal dose (p=0.02) and dose intensity (p<0.0001). This finding was confirmed in both validation cohorts (multivariate RR 2.1, 95% CI 1.2–3.8, p=0.01 and RR 1.5, 95% CI 1.01–2.26, p=0.04, respectively). Patients with low hematotoxicity have significantly higher failure rates despite higher doses and dose intensity. Hematotoxicity is an independent prognostic factor for treatment outcome. This observation suggests a strategy of individualized dosing adapted to hematotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–c.
Fig. 2.
Fig. 3a–c.
Fig. 4.

Similar content being viewed by others

References

  1. Chabner BA, Longo DL (eds) (1996) Cancer chemotherapy and biotherapy—principles and practice, 2nd edn. Lippincott-Raven, Philadelphia

  2. Perry MC (ed) (1996) The chemotherapy source book, 2nd edn. Williams & Wilkins, Philadelphia

  3. Tesch H, Diehl V, Lathan B, et al. (1998) Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood 92:4560–4567

    CAS  PubMed  Google Scholar 

  4. Engel C, Loeffler M, Schmitz S, et al. (2000) Acute haematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group (GHSG). Ann Oncol 11:1105–1114

    Article  CAS  PubMed  Google Scholar 

  5. Pfreundschuh M, Hasenclever D, Loeffler M, et al. (2001) Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. Ann Oncol 12:471–477

    Article  CAS  PubMed  Google Scholar 

  6. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590–2611

    CAS  PubMed  Google Scholar 

  7. Iyer L, Ratain MJ (1998) Pharmacogenetics and cancer chemotherapy. Eur J Cancer 34:1493–1499

    Article  CAS  PubMed  Google Scholar 

  8. Sulkes A, Collins JM (1987) Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71:229–233

    CAS  PubMed  Google Scholar 

  9. Evans WE, Crom WR, Stewart CF, et al. (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 18:359–362

    Article  Google Scholar 

  10. Sieber M, Rüffer U, Tesch H, et al. (1997) Rapidly alternating COPP+ABV+IMEP (CAI) is equally effective as alternating COPP+ABVD (CA) for Hodgkin’s disease: final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages (abstract). Blood 90 [Suppl 1]:586a

  11. Diehl V, Franklin J, Hasenclever D, et al. (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 16:3810–3821

    CAS  PubMed  Google Scholar 

  12. WHO (1979) WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva

  13. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514

    Google Scholar 

  14. Carpenter JT Jr, Maddox WA, Laws HL, et al. (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer 50:18–23

    PubMed  Google Scholar 

  15. Saarto T, Blomqvist C, Rissanen P, et al. (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301–305

    CAS  PubMed  Google Scholar 

  16. Poikonen P, Saarto T, Lundin J, et al. (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80:1763–1766

    Article  CAS  PubMed  Google Scholar 

  17. Cortes EP, Holland JF, Wang JJ, et al. (1974) Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 291:998–1000

    Google Scholar 

  18. McIntyre OR, Leone L, Pajak TF (1978) The use of intravenous melphalan (L-PAM) in the treatment of multiple myeloma (abstract). Blood 52 [Suppl 1]:274

  19. Piscitelli SC, Rodvold KA, Rushing DA, et al. (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555–561

    Google Scholar 

  20. Ratain MJ, Mick R, Schilsky RL, et al. (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9:1480–1486

    CAS  PubMed  Google Scholar 

  21. Miller AA, Tolley EA, Niell HB, et al. (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11:1179–1188

    CAS  PubMed  Google Scholar 

  22. Boddy AV, Yule SM, Wyllie R, et al. (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53:3758–3764

    Google Scholar 

  23. Van der Berg HW, Desai ZR, Wilson R, et al. (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215–219

    PubMed  Google Scholar 

  24. Rushing DA, Raber SR, Rodvold KA, et al. (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834–841

    CAS  PubMed  Google Scholar 

  25. Ratain MJ, Rosner G, Duggan D, et al. (1993) Population pharmacodynamic study of single-agent doxorubicin in women with stage III breast cancer (abstract 358). Proc Am Soc Clin Oncol 12:140

    Google Scholar 

  26. Bennett CL, Sinkule JA, Schilsky RL, et al. (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952–1956

    CAS  PubMed  Google Scholar 

  27. Preisler HD, Gessner T, Azarnia N, et al. (1984) Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12:125–130

    CAS  PubMed  Google Scholar 

  28. Rodman JH, Abromovitch M, Sinkule JA, et al. (1987) Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 5:1007–1014

    CAS  PubMed  Google Scholar 

  29. Evans WE, Crom WR, Abromovitch M, et al. (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471–477

    Google Scholar 

  30. Loeffler M, Hasenclever D, Diehl V (1998) Model based development of the BEACOPP regimen for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 9 [Suppl 5]:S73–S78

  31. Diehl V, Tesch H, Franklin J, et al. (1999) BEACOPP Chemotherapy for advanced Hodgkin’s disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation (abstract). Blood 94 [Suppl 1]:527a

Download references

Author information

Authors and Affiliations

  1. Coordinating Center for Clinical Trials, University of Leipzig, Prager Str. 34, 04317, Leipzig, Germany

    O. Brosteanu

  2. IMISE, University of Leipzig, Leipzig, Germany

    D. Hasenclever & M. Loeffler

  3. Clinic I for Internal Medicine, University of Cologne, Cologne, Germany

    V. Diehl

Authors
  1. O. Brosteanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Hasenclever
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Loeffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. German Hodgkin’s Lymphoma Study Group
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Brosteanu.

Additional information

The authors listed above wrote this contribution on behalf of the German Hodgkin’s Lymphoma Study Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brosteanu, O., Hasenclever, D., Loeffler, M. et al. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease. Ann Hematol 83, 176–182 (2004). https://doi.org/10.1007/s00277-003-0727-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0727-9

Keywords

Search

Navigation